Business Context and Reporting Period
Company: American BriVision (Holding) Corporation (also referenced as ABVC Biopharma, Inc.)
Filing Type: Form 8-K (Current Report)
Report Date: May 30, 2017
Event Date: May 26, 2017
Context: The Company holds an exclusive global license from BioLite Inc. for the "Sixth Product" for drug and therapeutic use. This filing reports the execution of a new co-development agreement.
Key Financial Metrics
This filing does not provide comprehensive financial statements (revenue, profit, cash flow, margins, debt, or liquidity). The only specific financial metric disclosed relates to the new agreement:
- Upfront Payment: Rgene Corporation agreed to pay the Company $3,000,000 in cash or stock.
- Payment Schedule: To be paid in three installments by August 15, 2017.
- Revenue Share: The Company is entitled to 50% of future net licensing income or net sales profit.
- Cost Sharing: Development costs are to be shared equally (50/50) between the parties.
Material Changes
The material change reported is the entry into a Co-Development Agreement with Rgene Corporation (Taiwan) on May 26, 2017. This agreement expands the commercialization strategy for the "Sixth Product" previously licensed from BioLite Inc. via an addendum dated January 12, 2017.
Guidance, Outlook, and Risks
Outlook: Management anticipates co-developing and commercializing products included in the Sixth Product with Rgene Corporation.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Specific risks cited include:
- Adverse decisions following reviews of additional safety information.
- Findings regarding clinical benefits that are inconsistent with recent publications.
- General uncertainties that could cause actual results to differ materially from expectations.
Unusual Items: The payment from Rgene may be made in cash or stock, introducing potential variability in the form of consideration received.
Investor Verification Checklist
- Verify the exact form of payment (cash vs. stock) and the specific dates for the three installments totaling $3,000,000.
- Review the full text of the Co-Development Agreement (Exhibit 99.1) for termination clauses and specific definitions of "net sales profit."
- Confirm the current development status and regulatory standing of the "Sixth Product" with BioLite Inc.
- Assess the financial stability and track record of Rgene Corporation as a development partner.